Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM
Without it, your body cannot function properly
In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet doses in patients with T2D, 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively
John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania and the lead author of the study, said
In short, GLP-1 therapy is powerful when needed medically
6 Emerging clinical applications 6.1 Non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) Studies investigating GLP-1 receptor agonists for the prevention of NAFLD/NASH indicate potential effectiveness via several molecular mechanisms